Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 11 (Table of Contents)
Published: 20 Nov-2013
DOI: 10.3833/pdr.v2013.i11.1991 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to increase its global footprint and offset declining revenues from its key pain products, acquisitive Endo Health Solutions has agreed to buy Paladin Labs in a mostly stock deal that values the Canadian company at approximately US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS